BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park JG. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clin Mol Hepatol. 2015;21:287-294. [PMID: 26527250 DOI: 10.3350/cmh.2015.21.3.287] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Pinter M, Sieghart W. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? Memo 2018;11:185-92. [PMID: 30220924 DOI: 10.1007/s12254-018-0431-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kumar P, Agarwal A, Singh AK, Gautam AK, Chakraborti S, Kumar U, Kumar D, Bhattacharya B, Panda P, Saha B, Qidwai T, Maity B, Saha S. Antineoplastic properties of zafirlukast against hepatocellular carcinoma via activation of mitochondrial mediated apoptosis. Regulatory Toxicology and Pharmacology 2019;109:104489. [DOI: 10.1016/j.yrtph.2019.104489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Byeon H, Lee SD, Hong EK, Lee DE, Kim BH, Seo Y, Joo J, Han SS, Kim SH, Park SJ. Long-term prognostic impact of osteopontin and Dickkopf-related protein 1 in patients with hepatocellular carcinoma after hepatectomy. Pathol Res Pract 2018;214:814-20. [PMID: 29753515 DOI: 10.1016/j.prp.2018.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Huang Y, Lu Y, Lu S. Sequential bilateral PVTT successfully controlled by radiotherapy and sorafenib, respectively. Kaohsiung J Med Sci 2019;35:63-4. [DOI: 10.1016/j.kjms.2018.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Singh AK, Bhadauria AS, Kumar U, Raj V, Rai A, Kumar P, Keshari AK, Kumar D, Maity B, Nath S, Prakash A, Saha S. Novel Indole-fused benzo-oxazepines (IFBOs) inhibit invasion of hepatocellular carcinoma by targeting IL-6 mediated JAK2/STAT3 oncogenic signals. Sci Rep 2018;8:5932. [PMID: 29651140 DOI: 10.1038/s41598-018-24288-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lee S, Lee M, Kim JB, Jo A, Cho EJ, Yu SJ, Lee JH, Yoon JH, Kim YJ. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. Biochem Biophys Res Commun 2016;473:1247-54. [PMID: 27091428 DOI: 10.1016/j.bbrc.2016.04.049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
7 Choi JH, Chung WJ, Bae SH, Song DS, Song MJ, Kim YS, Yim HJ, Jung YK, Suh SJ, Park JY, Kim DY, Kim SU, Cho SB. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82:469-478. [PMID: 29982870 DOI: 10.1007/s00280-018-3638-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
8 Yoon S, Lee EJ, Choi JH, Chung T, Kim DY, Im JY, Bae MH, Kwon JH, Kim HH, Kim HC, Park YN, Wang HJ, Woo HG. Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer. Oncogene 2018;37:4443-54. [PMID: 29720727 DOI: 10.1038/s41388-018-0291-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Moriya K, Namisaki T, Takaya H, Kaji K, Kawaratani H, Shimozato N, Sawada Y, Douhara A, Sato S, Furukawa M, Kitagawa K, Akahane T, Yoshiji H. Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. J Clin Med 2021;10:629. [PMID: 33562238 DOI: 10.3390/jcm10040629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Biomed Pharmacother 2016;83:607-16. [PMID: 27459117 DOI: 10.1016/j.biopha.2016.07.027] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
11 Singh AK, Bhadauria AS, Kumar U, Raj V, Maurya V, Kumar D, Maity B, Prakash A, De A, Samanta A, Saha S. Novel fused oxazepino-indoles (FOIs) attenuate liver carcinogenesis via IL-6/JAK2/STAT3 signaling blockade as evidenced through data-based mathematical modeling. Life Sciences 2018;201:161-72. [DOI: 10.1016/j.lfs.2018.02.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Qiu X, Wang X, Song Y, Chen L. Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma. Dig Dis Sci 2016;61:3513-21. [DOI: 10.1007/s10620-016-4270-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
13 Long HY, Huang TY, Xie XY, Long JT, Liu BX. Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World J Clin Cases 2021; 9(21): 5754-5768 [PMID: 34368295 DOI: 10.12998/wjcc.v9.i21.5754] [Reference Citation Analysis]
14 Tak KY, Nam HC, Choi JY, Yoon SK, Kim CW, Kim HY, Lee SW, Lee HL, Chang UI, Song DS, Yang JM, Kwon JH, Yoo SH, Sung PS, Choi SW, Song MJ, Kim SH, Jang JW. Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real‐life settings. Int J Cancer 2020;147:1970-8. [DOI: 10.1002/ijc.32964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 He S, Wei H, Ma Y, Zhao J, Xu W, Xiao J. Outcomes of metastatic spinal cord compression secondary to primary hepatocellular carcinoma with multidisciplinary treatments. Oncotarget 2017;8:43439-49. [PMID: 28404935 DOI: 10.18632/oncotarget.15708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
16 Lee HW, Kim HS, Kim SU, Kim DY, Kim BK, Park JY, Ahn SH, Jeon MY, Heo JY, Park SY, Lee YR, Jang SK, Lee SH, Jang SY, Tak WY, Han KH. Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. Gut Liver 2017;11:693-701. [PMID: 28651299 DOI: 10.5009/gnl16391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Bertacco A, Vitale A, Mescoli C, Cillo U. Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. Per Med 2020;17:83-7. [PMID: 32157952 DOI: 10.2217/pme-2018-0114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Park JG, Tak WY, Park SY, Kweon YO, Jang SY, Lee SH, Lee YR, Jang SK, Hur K, Lee HJ. Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report. Oncol Lett 2017;14:4853-6. [PMID: 29085491 DOI: 10.3892/ol.2017.6788] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
19 Tan ZB, Fan HJ, Wu YT, Xie LP, Bi YM, Xu HL, Chen HM, Li J, Liu B, Zhou YC. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling. J Ethnopharmacol 2019;232:62-72. [PMID: 30553869 DOI: 10.1016/j.jep.2018.12.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
20 Martens S, Jeong M, Tonnus W, Feldmann F, Hofmans S, Goossens V, Takahashi N, Bräsen JH, Lee EW, Van der Veken P, Joossens J, Augustyns K, Fulda S, Linkermann A, Song J, Vandenabeele P. Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Cell Death Dis 2017;8:e2904. [PMID: 28661484 DOI: 10.1038/cddis.2017.298] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]